Results 81 to 90 of about 1,978 (184)

Traditional health practitioners’ management of HIV/AIDS in rural South Africa in the era of widespread antiretroviral therapy [PDF]

, 2017
Background: Traditional health practitioners (THPs) have been identified as a key local resource in the fight against HIV/AIDS in South Africa. However, their approaches to the treatment of people living with HIV (PLHIV) have been met with skepticism by ...
Moshabela, Mosa, Rochat, Tamsen, Wight, Daniel, Zuma, Thembelihle   +3 more
core   +1 more source

Estimated impact of long‐acting injectable PrEP in South Africa: a model comparison analysis

Journal of the International AIDS Society, Volume 28, Issue S2, July 2025.
Abstract Introduction Long‐acting injectable cabotegravir (CAB‐LA) demonstrated superiority to daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for human immunodeficiency virus (HIV) pre‐exposure prophylaxis (PrEP) in two clinical trials. This analysis projects the impact of expanding PrEP coverage with CAB‐LA in South Africa between 2022 ...
Sarah E. Stansfield, Mia Moore, Lise Jamieson, Gesine Meyer‐Rath, Leigh F. Johnson, David Kaftan, Anna Bershteyn, Jennifer Smith, Valentina Cambiano, Loveleen Bansi‐Matharu, Andrew Phillips, Jesse Heitner, Ruanne V. Barnabas, Brett Hanscom, Deborah J. Donnell, Marie‐Claude Boily, Dobromir Dimitrov   +16 more
wiley   +1 more source

Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost‐effectiveness [PDF]

Journal of the International AIDS Society, 2019
AbstractIntroductionA vaginal ring containing dapivirine is effective for HIV prevention as pre‐exposure prophylaxis (PrEP). We evaluated the potential epidemiological impact and cost‐effectiveness of dapivirine vaginal ring PrEP among 22‐ to 45‐year‐old women in KwaZulu‐Natal, South Africa.MethodsUsing mathematical modelling, we studied dapivirine ...
Robert Glaubius, Yajun Ding, Kerri J Penrose, Greg Hood, Erik Engquist, John W Mellors, Urvi M Parikh, Ume L Abbas   +7 more
openaire   +2 more sources

Recent advances in pre-exposure prophylaxis for HIV [PDF]

, 2017
Although pre-exposure prophylaxis (PrEP)-the use of antiretroviral drugs by non-infected people to prevent the acquisition of HIV-is a promising preventive option, important public health questions remain.
Desai, M, Field, N, Grant, R, McCormack, S   +3 more
core   +1 more source

PrEParing for choice in a new era of HIV prevention [PDF]

, 2023
In The Lancet HIV, Gonasagrie Nair and colleagues1 report the findings from the MTN-34/REACH trial, which investigated the safety of, adherence to, and preferences for HIV pre-exposure prophylaxis (PrEP) among adolescent girls and young women.
Chi, Benjamin H, Graybill, Lauren A
core   +2 more sources

Highlights from the 9th IAS conference on HIV science, 23-26 July 2017, Paris, France [PDF]

, 2017
The 9th International AIDS Society Conference on HIV Science (IAS 2017) took place at the Palais des Congrès, in Paris, France, from 23 to 26 July 2017, chaired by Linda-Gail Bekker and Jean-François Delfraissy. It was organised by the International AIDS
Barber, Tristan J, Kinloch-de Loës, Sabine, Psomas, Christina K, Rutsaert, Sofie   +3 more
core   +2 more sources

A model of HIV/AIDS population dynamics including ARV treatment and pre-exposure prophylaxis [PDF]

, 2018
Antiretroviral treatment (ART) and oral pre-exposure prophylaxis (PrEP) have recently been used efficiently in management of HIV infection. Pre-exposure prophylaxis consists in the use of an antiretroviral medication to prevent the acquisition of HIV ...
CP Bhunu, D Kerrigan, EF Drabo, EJ Arts, F Nyabadza, H Grant, JM Baeten, JM Hyman, Joint United Nations Programme on HIV/AIDS, L Hassan, Mozart U Nsuami, P Driessche van den, Peter J Witbooi, R Eakle, RM Anderson, SANA Council, SD Hove-Musekwa, World Health Organization, Z Mukandavire   +18 more
core   +2 more sources

Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings [PDF]

JAIDS Journal of Acquired Immune Deficiency Syndromes, 2015
Variable adherence limits effectiveness of daily oral and intravaginal tenofovir-containing pre-exposure prophylaxis. Monthly vaginal antiretroviral rings are one approach to improve adherence and drug delivery.MTN-013/IPM 026, a multisite, double-blind, randomized, placebo-controlled trial in 48 HIV-negative US women, evaluated vaginal rings ...
Beatrice A, Chen, Lori, Panther, Mark A, Marzinke, Craig W, Hendrix, Craig J, Hoesley, Ariane, van der Straten, Marla J, Husnik, Lydia, Soto-Torres, Annalene, Nel, Sherri, Johnson, Nicola, Richardson-Harman, Lorna K, Rabe, Charlene S, Dezzutti   +12 more
openaire   +2 more sources

Vaginal rings for delivery of HIV microbicides

International Journal of Women's Health, 2012
R Karl Malcolm, Susan M Fetherston, Clare F McCoy, Peter Boyd, Ian MajorSchool of Pharmacy, Queen's University Belfast, Belfast, UKAbstract: Following the successful development of long-acting steroid-releasing vaginal ring devices for the ...
McCoy CF, Fetherston SM, Malcolm RK, Boyd P, Major I   +4 more
doaj  

Characterization of porous, dexamethasone-releasing polyurethane coatings for glucose sensors. [PDF]

, 2014
Commercially available implantable needle-type glucose sensors for diabetes management are robust analytically but can be unreliable clinically primarily due to tissue-sensor interactions.
Klitzman, Bruce, Reichert, William M, Vallejo-Heligon, Suzana G   +2 more
core   +1 more source